AIM ImmunoTech Inc.
AIM
$0.26
$0.00-1.83%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -35.62% | -48.24% | -41.05% | -39.80% | -24.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.62% | -48.24% | -41.05% | -39.80% | -24.35% |
| Cost of Revenue | 269.70% | 312.90% | 163.89% | -39.66% | -34.00% |
| Gross Profit | -124.78% | -128.78% | -88.96% | -39.86% | -20.98% |
| SG&A Expenses | -43.97% | -43.38% | -50.08% | -49.63% | -44.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.78% | -41.07% | -47.78% | -47.37% | -46.93% |
| Operating Income | 41.83% | 41.01% | 47.83% | 47.42% | 47.06% |
| Income Before Tax | 12.70% | 19.41% | 34.18% | 42.36% | 51.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.70% | 19.41% | 34.18% | 42.36% | 51.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.70% | 19.41% | 34.18% | 42.36% | 51.13% |
| EBIT | 41.83% | 41.01% | 47.83% | 47.42% | 47.06% |
| EBITDA | 42.13% | 41.34% | 48.21% | 47.80% | 47.41% |
| EPS Basic | 69.85% | 61.39% | 58.04% | 56.65% | 61.51% |
| Normalized Basic EPS | 64.05% | 56.38% | 56.42% | 56.23% | 61.35% |
| EPS Diluted | 69.85% | 61.39% | 58.04% | 56.65% | 61.51% |
| Normalized Diluted EPS | 64.05% | 56.38% | 56.42% | 56.23% | 61.35% |
| Average Basic Shares Outstanding | 312.23% | 187.68% | 100.76% | 33.94% | 25.16% |
| Average Diluted Shares Outstanding | 312.23% | 187.68% | 100.76% | 33.94% | 25.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |